The Montreal-Boston Collaborative group co-founded the NIDDK IBD Genetics Consortium in 2002. Since then, our group has played a pivotal role in the identification of >150 genetic risk factors for IBD and made significant advances in the understanding their role in health and disease. The current proposal is meant to build on our successes and to support (1) our recruitment of IBD patients and healthy controls for the publicly-available NIDDK Repository, (2) our efforts to identify key genetic risk factors for IBD, and (3) our innovative work in understanding the biological basis of IBD. There is no doubt that the success of the genome-wide association studies (GWAS) in identifying genetic risk factors for IBD (>150 independent risk factors) presents us with new challenges to be faced in the years ahead. The primary challenge is how we can translate these genetic discoveries into a more comprehensive biological understanding of IBD pathogenesis. What is equally clear, although there are some notable exceptions (e.g. IL23R, ATG16L1) GWA studies have not directly led to the causal genes or specific functional variants, and this has greatly limited the ability to extract causal biology from these discoveries. Recently, however, we have demonstrated conclusively how sequencing of IBD genes has led to (1) the identification of the causal gene within regions harboring multiple candidates, and (2) the identification of rarer, higher penetrance alleles with more obvious functional consequence than the low penetrance, non- coding variants that have led to the discovery of these regions. These are critical steps for the genetic study of IBD as they will enable us to interpret the biological insight from the GWAS findings much more directly and precisely, providing a bridge from GWAS associations to functional biology. We have two main objectives: (1) To develop patient and control resources that will enhance the Consortium's capacity to identify genes, genetic variation and biological mechanisms contributing to the pathogenesis of IBD, and (2) To obtain a biologic understanding how specific rare genetic variants in associated genes predispose or protect an individual from developing IBD. In order to meet our first objective, we will take advantage of our network of >10 university-based hospitals with dedicated IBD clinics that has a proven track record of 10+ years in the recruitment of individuals for IBD genetic studies for the NIDDK IBD Genetics Consortium and the publicly-available NIDDK Repository. For our second objective, we will combine unique state-of-the-art gene sequencing data and genome-wide genetic data in order to identify rare causal genetic variation and innovative integrative biology approaches to demonstrate the role that this genetic variation has in determining why some individuals develop IBD and why others are protected from these diseases.
The Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are characterized by chronic relapsing inflammation of the gastrointestinal trat and have an important impact on health, economic and social welfare systems, as a consequence of the morbidity associated with these diseases. IBD can affect anyone at any age with the majority of cases being diagnosed in adolescents and young adults;this is a crucial time of life for an individual's education, the ability to establish a stable financial footing andto launch a career and family. The Montreal-Boston Collaborative Group has, over the last ten years, played a pivotal role within the NIDDK IBD Genetics Consortium in the identification of >150 genetic risk factors for IBD and made significant advances in the understanding their role in health and disease. The current proposal is to support (1) our recruitment of IBD patients and healthy controls for the publicly-available NIDDK Repository, (2) our efforts to identify key genetic risk factors for IBD, and (3) our innovative work in understanding the biological basis of IBD.
|Mohanan, Vishnu; Nakata, Toru; Desch, A Nicole et al. (2018) C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. Science 359:1161-1166|
|Hinks, Anne; Marion, Miranda C; Cobb, Joanna et al. (2018) Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70:957-962|
|Jijon, H B; Suarez-Lopez, L; Diaz, O E et al. (2018) Intestinal epithelial cell-specific RAR? depletion results in aberrant epithelial cell homeostasis and underdeveloped immune system. Mucosal Immunol 11:703-715|
|Johannessen, Liv; Sundberg, Thomas B; O'Connell, Daniel J et al. (2017) Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nat Chem Biol 13:1102-1108|
|Brant, Steven R; Okou, David T; Simpson, Claire L et al. (2017) Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology 152:206-217.e2|
|Misra, Ravi; Arebi, Naila (2017) Re: Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease. Gastroenterology 152:2082-2083|
|Huang, Hailiang; Fang, Ming; Jostins, Luke et al. (2017) Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature 547:173-178|
|Hinks, A; Bowes, J; Cobb, J et al. (2017) Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. Ann Rheum Dis 76:765-772|
|Parian, Alyssa; Limketkai, Berkeley; Koh, Joyce et al. (2017) Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis. Gut 66:1390-1397|
|Kopylov, Uri; Boucher, Gabrielle; Waterman, Matti et al. (2016) Genetic Predictors of Benign Course of Ulcerative Colitis-A North American Inflammatory Bowel Disease Genetics Consortium Study. Inflamm Bowel Dis 22:2311-6|
Showing the most recent 10 out of 67 publications